Our read is that individuals should avoid seed oils due to their potential negative impact on metabolic health and increased disease risk.
Our read is that seed oils, particularly those high in linoleic acid, are implicated in various health issues, including metabolic dysfunction, increased cancer risk, and cardiovascular mortality.
Experts suggest that avoiding processed seed oils and reducing linoleic acid intake are crucial steps for improving overall health and preventing chronic conditions.
The processing methods of seed oils and their prevalence in Western diets and processed foods raise significant concerns about their long-term effects on human health.
To reduce linoleic acid intake, Paul Saladino advises avoiding chicken and pork fed corn and soy, consuming nose-to-tail animal foods, and cutting out seed oils and processed sugars.
Paul Saladino notes that conflicting evidence on seed oils may stem from observational studies, oil freshness, study duration, and genetic differences in linoleic acid metabolism. He also points out that the seed oil industry has a significant financial interest influencing public perception, as evidenced by 'heart healthy' labeling, and that manufacturers can label products containing canola oil as 'glucose control' or 'balanced nutritional drinks' despite canola oil's negative long-term effects on blood sugar, insulin resistance, and metabolic dysfunction. Paul Saladino also mentions that Dariusafarain, who conducted a meta-analysis on seed oils, has received consulting payments from processed food companies and industry lobbying groups, and that the American Heart Association certifies soybean oil, which is approximately 55% linoleic acid, as a healthy oil.
A change in the verdict would require new evidence demonstrating that the chemical processing of seed oils does not result in harmful contaminants or oxidation, that linoleic acid from seed oils does not impair mitochondrial function or increase disease risk, or that the long-term consumption of seed oils is consistently associated with positive health outcomes in human randomized controlled trials.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The effect size is large enough to matter clinically, not just statistically.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Animal-model results don't translate to the human protocol being recommended.